Switch to:
» Details

Insider Trades

Latest Guru Trades with BICX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care    NAICS: 621498    SIC: 8093
Compare:OTCPK:PFHO, OTCPK:SPIN, OTCPK:CPAI, AMEX:HH, AMEX:SSY, OTCPK:WNDM, OTCPK:FDNH, OTCPK:USNU, OTCPK:GRST, OTCPK:CAMDF, AMEX:AMS, OTCPK:BNKL, OTCPK:CCEL, OTCPK:FCHS, NAS:JYNT, OTCPK:MIHI, OTCPK:AMEH, OTCPK:CATS, NYSE:ADPT, AMEX:HLTH » details
BioCorRx Inc is an alcohol treatment and rehabilitation company. It provides an alcoholism treatment program that empowers patients to succeed in their overall recovery.

Fresh Start Private Management, Inc., a Nevada corporation on January 28, 2008 as Cetrone Energy Company. On July 26, 2010, the Company changed its name to Fresh Start Private Management Inc. Through its wholly owned subsidiary, it is an alcohol rehabilitation and treatment center. The company was established in January 2010 and is currently operating in Santa Ana, California. Its alcohol rehabilitation program consists of a Naltrexone implant that is placed under the skin in the lower abdomen coupled with life counseling sessions from specialized counselors. The Company operates within the Specialty Hospitals, Expert Psychiatric industry, specifically within the industry subsets of Alcoholism Rehabilitation Hospital. It has created an innovative alcohol treatment program that empowers patients to succeed in their overall recovery. The Company offers a treatment philosophy that combines medical intervention, a singular focus and a comprehensive approach, and a focus on family and friends. It has been operating for approximately 36 months and has treated over 150 patients. Currently, it is treating about 2 to 3 patients per week. The alcohol treatment services costs an average of $49,300 per patient and is typically covered by insurance. The Company faces competition with the other rehabilitation service providers.

Top Ranked Articles about BioCorRx Inc

Naltrexone Showing More Potential in Drug Addiction Treatment Market Teva Pharmaceuticals and Alkermes produce 2 main forms of treatment
In the on-going debate of which drug addiction treatment is more effective, naltrexone is showing more potential than buprenorphine, according to the latest study by researchers from Columbia University. Read more...
BioCorRx Receives New Funding for Opioid Drug 21st Century Cures Act promises $1 billion in research funding
The signing last month of the 21st Century Cures Act into law by President Barack Obama signals a major revamp in the treatment of opioid addiction because of the promise of $1 billion in research funding, as well as a system to hasten approval of drugs and medicine devices by the Food and Drug Administration. Read more...
» More Articles for BICX

Ratios

vs
industry
vs
history
PS Ratio 23.33
BICX's PS Ratio is ranked lower than
99.99% of the 256 Companies
in the Global Medical Care industry.

( Industry Median: 1.67 vs. BICX: 23.33 )
Ranked among companies with meaningful PS Ratio only.
BICX' s PS Ratio Range Over the Past 10 Years
Min: 0.95  Med: 5.56 Max: 185
Current: 23.33
0.95
185
Current Ratio 0.10
BICX's Current Ratio is ranked lower than
99.99% of the 238 Companies
in the Global Medical Care industry.

( Industry Median: 1.29 vs. BICX: 0.10 )
Ranked among companies with meaningful Current Ratio only.
BICX' s Current Ratio Range Over the Past 10 Years
Min: 0.05  Med: 0.5 Max: 5.44
Current: 0.1
0.05
5.44
Quick Ratio 0.10
BICX's Quick Ratio is ranked lower than
99.99% of the 238 Companies
in the Global Medical Care industry.

( Industry Median: 1.15 vs. BICX: 0.10 )
Ranked among companies with meaningful Quick Ratio only.
BICX' s Quick Ratio Range Over the Past 10 Years
Min: 0.05  Med: 0.5 Max: 5.44
Current: 0.1
0.05
5.44
Days Sales Outstanding 36.00
BICX's Days Sales Outstanding is ranked lower than
99.99% of the 204 Companies
in the Global Medical Care industry.

( Industry Median: 42.10 vs. BICX: 36.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
BICX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 11.05  Med: 160.29 Max: 452.04
Current: 36
11.05
452.04
Days Payable 2.00
BICX's Days Payable is ranked lower than
99.99% of the 157 Companies
in the Global Medical Care industry.

( Industry Median: 39.14 vs. BICX: 2.00 )
Ranked among companies with meaningful Days Payable only.
BICX' s Days Payable Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2
Current: 2
0
2

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -17.70
BICX's 3-Year Average Share Buyback Ratio is ranked lower than
99.99% of the 121 Companies
in the Global Medical Care industry.

( Industry Median: -2.50 vs. BICX: -17.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BICX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -19  Med: -7.3 Max: 39.3
Current: -17.7
-19
39.3

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 3.50
BICX's Price-to-Median-PS-Value is ranked lower than
99.99% of the 227 Companies
in the Global Medical Care industry.

( Industry Median: 1.03 vs. BICX: 3.50 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BICX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.25  Med: 1 Max: 13
Current: 3.5
0.25
13
Earnings Yield (Greenblatt) % -15.37
BICX's Earnings Yield (Greenblatt) % is ranked lower than
99.99% of the 257 Companies
in the Global Medical Care industry.

( Industry Median: 3.90 vs. BICX: -15.37 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BICX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -58.35  Med: 0 Max: 0
Current: -15.37
-58.35
0

More Statistics

Revenue (TTM) (Mil) $0.66
EPS (TTM) $ -0.03
Beta-0.37
Short Percentage of Float0.00%
52-Week Range $0.01 - 0.10
Shares Outstanding (Mil)169.89
» More Articles for BICX

Headlines

Articles On GuruFocus.com
ANGEL Program Gets National Attention Feb 13 2017 
Naltrexone Showing More Potential in Drug Addiction Treatment Market Feb 05 2017 
BioCorRx Receives New Funding for Opioid Drug Jan 22 2017 
US Prisons Experiment With Addiction Treatment for Inmates Nov 29 2016 
Health Care Sector in an Upward Climb in June Jun 12 2014 
Two Promising Health Care Stocks with Market Capitalizations Under $500 Million Jun 11 2014 

More From Other Websites
BioCorRx Provides Preclinical Study Update on BICX101 Development Feb 23 2017
Drug Addiction Treatment Stocks to Watch Feb 22 2017
BioCorRx Announces the Appointment of Dr. Balbir S. Brar as VP of Drug Development Feb 21 2017
ANGEL Program Gets National Attention Feb 13 2017
BioCorRx Provides Business Update Webcast Feb 10 2017
BioCorRx to Collaborate with the City of Anaheim to Treat Opioid and Alcohol Addiction Feb 08 2017
BIOCORRX INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Feb 08 2017
Naltrexone Showing More Potential in Drug Addiction Treatment Market Feb 05 2017
BioCorRx Receives New Funding for Opioid Drug Jan 22 2017
JGR Capital Partners Initiates Coverage on BioCorRx Inc. with a Price Target of $0.09 Jan 19 2017
BioCorRx Retains Innovative Science Solutions to Guide FDA Regulatory Process for its Naltrexone... Jan 12 2017
BIOCORRX INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of... Jan 06 2017
BioCorRx Inc. to Present at the 9th Annual LD Micro Main Event Dec 02 2016
BIOCORRX INC. Files SEC form 8-K, Material Modification to Rights of Security Holders, Amendments to... Nov 30 2016
BioCorRx Selects Covance for Non-Clinical Studies, Announces the Addition of Dr. Bal S. Brar to its... Nov 28 2016
BIOCORRX INC. Financials Nov 24 2016
BioCorRx, Inc. :BICX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 18, 2016 Nov 18 2016
BIOCORRX INC. Files SEC form 10-Q, Quarterly Report Nov 17 2016
BIOCORRX INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Oct 27 2016
BioCorRx Inc. to Host Corporate Update Webinar on Wednesday, October 12th at 2:00 p.m. Eastern Time Oct 06 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK